

Up-scaling the global univocal identification of medicines

Best practise / knowledge sharing workshop Procedural Change with IDMP WP 04

INFARMED - National Authority of Medicines and Health Products, I.P. 2024-04-02

Rui Vilar



### **INFARMED**








### **Future system**







# **Dataflow**





Work ongoing at EMA to make PMS the place for all published validated product data in EU in IDMP structure.

Product data for nationally authorised

products are provided by industry

checked/validated by EMA (e.g. compliance to the current SmPC) but is not checked by the national authorities authorising these products.\*

directly to PMS and are

Infarmed

Autoridade Nacional do Medicamento

NAC, MPR, DCP

Cross-border eprescription system In all these dataflows, there is an aim to move to ISO IDMP structure to facilitate the data exchange.



(eA**F**)

Pharmaceutica/

companies

Marketing Authorisation

Applications (eAF) within

centralised procedures.

EMA before upload.

The application is assessed

and the product data for all

by the EC is validated by

products centrally authorised

Data provided to the "Article 57-database" for all authorised products in accordance with EC 726/2004 art.57(2) and then onwards to the PMS database (in IDMP format).

(National portal

(SMUH)+CESP)

Product Masterdata

System (PMS)

Product data on all products authorised for marketing in Portugal is checked/validated by PT INFARMED.

CP

National Database: **GIMED** 

Serviços Partilhados do Ministério da Saúde

National eHealth agency

Data on medical products including package info, prince info. reimbursement.





**Hospitals** 



**Pharmacies** 



Healthcare

Marketing Authorisation Applications (SMUH + CESP) within national, decentralised and mutual recognition procedures

(for national authorisation).

\*) For PMS, there are ongoing discussions on if and how the data for products authorised within national procedures could be validated by the NCAs in the future, but no decisions are taken yet. Until then, the national product databases are the only place to find published validated product data for nationally authorised products.



# **Working data – New marketing authorisations**













Medicines database

portal

**OMS RMS** 

**Process** management system

- **Manufacturers**
- Active substances and excipients
- Packages
- Pharmaceutical form
- Product name
- Shelf life
- Special precautions for storage








# **Working data - Variations**







### **Working data - Organisations**














Entity ≎	Address ≎	Version	Additional Info. ≎	Start Date ≎	End Date ≎
Bayer Bitterfeld GmbH (Fab. Bitterfeld - Wolfen)	Ortsteil Greppin, Salegaster Chaussee 1 - 06803 - Bitterfeld - Wolfen - Bitterfeld - Wolfen - DE	100		28-07-2010	
Bayer Bitterfeld GmbH (Fab. Greppin)	Salegaster Chausse, 1 - D-06803 - Greppin - Greppin - DE	100		14-07-1995	28-07-2010

- ► Historical data on organisations Start Date and End Date
- National submission portal: currently approved
- Variations: automatic update of medicines database








# **Working data - Organisations**





### National organisations database



### Organisations SOP

- New/changes also validated against OMS
- ORG ID and LOC ID in database
- Data quality



### **Working data - Substances**













Substance ≎	Function \$	Operator \$	Quant. 1
Starch maize	Excipient		10
Microcrystalli ne cellulose	Excipient		10

- National submission portal: currently approved formula
- ► Variations: automatic update of medicines database







### **Working data - Substances**





#### National substances database



#### Substances SOP


- New/changes
- > SMS ID
- Data quality



# **Working data - Referentials**



► New system for referentials





# **Working data - referentials**



► Ingredient Role list



Active
Excipient
Flavor
Preservative
Propellant
Solvent
Coating
Reagent
Printing ink

Active **Excipient Solvent / Diluent** Adjuvant Starting material for excipient Raw materials used in the manufacture of the product Starting material for active substance Overage





# **Working data - referentials**



Manufacturing Activity list



Manufacturer

Responsible for Batch Release

Labelling

Bulk Manufacturer X

Manufacturer responsible for batch certification

Primary packaging

Processing operations for the medicinal product





### Working data - referentials



Legal Status for the Supply list



Medicines database



Medicinal product subject to restricted medical prescription – a), b), c)

Medicinal product subject to restricted medical prescription

Medicinal product not subject to medical prescription - pharmacy only






Medicinal product on medical prescription renewable delivery / non-renewable delivery / renewable or non-renewable delivery / exempt for some presentations



### **Working data - PMS**













Process management system

GiMED

- Packages
- Product names
- ► Shelf life
- Special precautions for storage








### **Working data - PMS**





Approx. 2900 between 2019-2023





### **Procedural Change with IDMP**



- As IDMP implementation spreads more in INFARMED, different departments will have to include IDMP in their procedures
- National specificity: submission portals
- Where in the flow is data being entered manually IDMP an opportunity to automate
- Where and how to introduce right now procedural changes to start progressing as much as possible in SPOR and IDMP without having to wait for major changes in the systems or databases
- Substances, organisations and some RMS lists seem to be the best candidates
- Cultural change





### Thank you for your attention.

